The aim of this study was to determine whether constitutive ErbB2 activation controls growth and apoptosis in colon cancer cells. Growth arrested GEO cells showed constitutive activation of ErbB2 in the absence of exogenous growth factors or serum supplementation. Higher levels of heregulin and ErbB2 activation were observed in the growth-arrested state and cell cycle re-entry was independent of exogenous growth factors. Blockade of ErbB2 activation by heregulin neutralizing antibodies and by AG879 resulted in prevention of cell cycle re-entry. This indicated that autocrine heregulin activity was responsible for growth factor independence and for cell cycle re-entry. Activation of ErbB2 was the result of heregulin mediated interaction with ErbB3 and generated downstream activation of the ERK and the PI3K/AKT pathways. Heregulin neutralizing antibody treatment of growth arrested GEO cells also generated apoptosis as re¯ected by PARP cleavage and DNA fragmentation indicating a cell survival signal was also induced by the constitutively activated ErbB2. The activation of AKT but not the MAPK pathway was responsible for cell survival in these cells.
Introduction
Members of the epidermal growth factor (EGF) receptor family consist of four members: ErbB1 or epidermal growth factor (EGF) receptor, ErbB2 (neu, HER2) ErbB3 and ErbB4. There are several ligands that bind the ErbB receptors. These ligands fall into the EGF like those which bind ErbB1; those which bind ErbB1 and ErbB4 such as betacellulin and neu dierentiation factors, or heregulin a and b, which bind ErbB3, and ErbB4 (Riese and Stern, 1998) . Ligand binding results in receptor homo-and heterodimerization leading to phosphorylation of tyrosine residues, which serve as docking sites for intracellular signaling proteins. ErbB2 is the preferred heterodimerization partner of the other ErbB receptors (Graus-Porta et al., 1997; Karunagaran et al., 1996) .
Heregulins are ligands for erbB3 and erbB4 (Carraway and Cantley, 1994; Plowman et al., 1993) . Heregulin binding to erbB3 or erbB4 induces noncovalent heterodimeric complexes of the receptor with erbB2 thus leading to ErbB2 activation and transphosphorylation of ErbB3 (Alimandi et al., 1995; Carraway and Cantley, 1994; Tzahar et al., 1996; Wallasch et al., 1995) . The activation of ErbB family receptors initiates a variety of signal cascades including the PI3K/AKT and MAPK pathways, which are commonly essential for proliferation and dierentiation (Cobb and Goldsmith, 1995; Egan and Weinberg, 1993) . Heregulin mediated ErbB activation has been shown to stimulate mammary epithelial cells as well as mammary tumor cell lines, which express low levels of ErbB2 receptor Graus-Porta et al., 1995; Lewis et al., 1996; Marte et al., 1995) . However heregulins can have a growth inhibitory eect in other breast tumor cell lines .
ErbB2 expression is frequently elevated in human tumors of epithelial origin, especially of breast and ovary (Klapper et al., 2000) . Although, it is rarely over expressed, ErbB2 is widely expressed at`normal' levels in colon cancers suggesting a possible growth regulatory role for this ErbB family member in this disease.
In this study we examined the expression level and the state of activation of erbB2 in human colon cancer cells. We show that heregulin is co-expressed with erbB2 expression in colon cancer specimens and that autocrine activation of erbB2 occurs through dimerization to erbB3 in a colon carcinoma cell line. In growth arrested GEO colon cancer cells, autocrine heregulin generates constitutive activation of ErbB2. Constitutive ErbB family activation is associated with several types of cancer in addition to breast cancer (Ram and Ethier, 1996; Worthylake et al., 1999) . The heregulin mediated constitutive activation of ErbB2 generates growth factor independence of growth arrested GEO colon cancer cells for re-entry into the cell cycle and provides the cells with a cell survival mechanism during growth factor and nutrient depletion. To our knowledge this is the ®rst demonstration of autocrine heregulin mediated growth factor independence.
Results

ErbB2 levels in colon cancer
Heregulin and its associated ErbB family members have been implicated in neoplastic progression of breast and ovarian cancer Lewis et al., 1996) . We examined human colon carcinoma for immunohistochemical expression of erbB2 and heregulin to determine the plausibility of a role in the growth regulation and progression of colon cancer. Sections of colon carcinoma stained with antibodies to ErbB2 and heregulin showed signi®cant staining of ErbB2 relative to staining with a non-speci®c antibody and demonstrated a strong co-localization with heregulin ( Figure 1a ). Similar co-localization of erbB2 and heregulin was seen in sections from the GEO-SF xenografts (Figure 1b) . Co-expression of heregulin and erbB2 in colon adenomas and cancer suggest an autocrine mechanism for tumor growth.
ErbB2 and heregulin levels in colon cancer cell lines
We compared ErbB2 and heregulin expression levels in colon and breast cancer cell lines by Western analysis. Each colon carcinoma line had comparable levels of ErbB2 to that of MCF7 cells, while having substantially lower levels of ErbB2 than SKBR-3 (Figure 2 ). The level of heregulin in colon cancer cell lines was higher than that of MCF7 and comparable to SKBR3 breast cancer cell lines (Figure 2 ). We next examined the levels of activated ErbB2 in dierent growth phases in tissue culture. We have previously shown that autocrine TGFa was up regulated as a function of growth state in highly progressed, growth factor independent colon carcinoma cells (Howell et al., 1998; Jiang et al., 1998) . Activation of ErbB2 in GEO cells was higher in the quiescent state than the other phases of growth ( Figure 3 ). Constitutive Figure 1 Immunohistochemical staining of human colon adenocarcinoma (a) and GEO xenograft tissue (b) for the expression of ErbB2 (ErbB2) and heregulin (Hrg). Serial sections from paran embedded blocks of these tissues were examined using a modi®ed avidin-biotin method. Sections from these tissues stained with normal IgG served as a negative (Neg) control for nonspeci®c staining Oncogene Constitutive ErbB2 activation in colon cancer S Venkateswarlu et al activation of ErbB2 in a growth factor free, growth arrested state implied that ErbB2 was under control of an autocrine growth factor, perhaps heregulin. Examination of cells in dierent growth phases revealed that heregulin expression was also high in growth arrest (Figure 3 ).
ErbB3 is a dimerization partner of ErbB2 in quiescent GEO cells
We examined cell lysates for ErbB2 activation partners by immunoprecipitation followed by Western blot analysis. Western analyses of EGF receptor, ErbB3 and ErbB4 receptor were performed on ErbB2 immunoprecipitates. ErbB3 appeared to be the only prominent dimerization partner of ErbB2 in quiescent cells lacking exogenous growth factors (Figure 4a ). This suggested that the constitutive activation of ErbB2 in growth arrest is through heregulin binding to ErbB3 and heterodimerization with ErbB2. Samples were also immunoprecipitated with individual ErbB receptors followed by an immunoblot with an antiphosphotyrosine antibody. The blots were stripped and immunoblotted with antibodies against individual ErbB receptors (Figure 4b ).
Neutralizing antibody to heregulin inhibits the activation of ErbB2
We used neutralizing antibodies to heregulin to ascertain whether endogenous heregulin was responsible for activating ErbB2 in quiescent cells. Growth arrested GEO cells were treated with 8 mg/ml of neutralizing antibody to heregulin 24 h prior to collection of cell lysates. We compared heregulin neutralizing antibody treatment to that with a tyrphostin derivative (AG879), a highly selective phosphorylation inhibitor and a positive control for inhibition of ErbB2 (Qiu et al., 1998) . AG879 acts as competitive inhibitor of the ATP binding site of erbB2 (Levitzki and Gazit, 1995) . The concentration used in this study does not inhibit basal EGFR activation in other colon cancer cell lines with high constitutive EGFR activation (data not shown). The structures of the ATP binding sites are closely related in the EGFR and ErbB2, consequently re¯ecting the high selectivity of AG879 for ErbB2. AG879 (3 mM) and the neutralizing antibody to heregulin (8 mg/ml) both inhibited the activation of ErbB2 ( Figure 5 ).
Mitogenesis assay
We hypothesized that autocrine heregulin in growth arrested GEO cells would make these cells growth factor independent, enabling them to re-enter the cell cycle in the absence of exogenously added growth factors. We used a mitogenesis assay to test the increased growth factor independence of GEO as a result of the heregulin-induced activation of ErbB2. Quiescent GEO cells required only the addition of fresh nutrients alone for re-entry into the cell cycle and induction of DNA synthesis. The resultant level of DNA synthesis by nutrient replenishment was comparable to that of cells released with medium containing nutrients, insulin, transferrin and EGF (SF). However when the growth arrested GEO cells treated with heregulin neutralizing antibody were replenished with nutrients alone the amount of DNA synthesis decreased by 70%, indicating that autocrine heregulin enhances re-entry into the cell cycle under conditions not optimal for growth ( Figure 6 ).
Autocrine heregulin activates the MAPK and PI3K/AKT pathways
Heregulin activates ErbB2 through binding to ErbB3 and ErbB4 receptors and initiates a cascade of events resulting in the activation of phosphatidyl inositol 3-kinase (PI3K) and MAPK pathways. The PI3K pathway regulates the phosphorylation and activity of p70S6 kinase and AKT. Activated AKT has been shown to be a survival signal that protects the cells from apoptosis and p70S6 kinase mediates growth factor induced cell proliferation (Carpenter and Cantley, 1996; Coer et al., 1998) . Studies have shown that exogenous heregulin can induce activation of ERK1/2 in mammary epithelial cells (Altiok et al., 1997) . We examined growth arrested GEO cells expressing autocrine heregulin for constitutive activation of downstream signaling intermediates. These cells showed activation of PI3K and the MAPK pathways as indicated by the activation of AKT and ERK1/2. Treatment of cells with neutralizing antibody to heregulin or AG879 inhibited this activation as re¯ected by the loss of phosphorylation of AKT, p70S6 kinase and ERK1/2 (Figure 7) . A selective PI3K inhibitor, LY290042 was used as a control for inactivation of the PI3K pathway (Vlahos et al., 1995) . Cells were treated with PD98059, a selective inhibitor of MEK, as a positive control for inhibition of the MAPK pathway (Alessi et al., 1995; Dudley et al., 1995; Pang et al., 1995) . LY290042 inhibited the activation of AKT (Figure 7a ) and PD98059 inhibited the activation of ERK1/2 ( Figure   Figure 5 Blockade of ErB2 activation with heregulin neutralizing antibody. GEO cells rendered quiescent were treated with heregulin neutralizing antibody, normal IgG or with AG879 medium at the concentrations of 8 mg/ml, 8 mg/ml and 3mM respectively. Untreated cells served as a treatment control (C). Equivalent amounts of cell lysates from these cells were analysed by Western blot analysis with an anti-phospho EB2 antibody. Total actin was determined using an anti-actin antibody as a control for normalization of protein loading Figure 6 Mitogenesis assay. GEO cells rendered quiescent were either left untreated with no change of medium (NC) Figure 7 Activation of PI3K and MAPK pathways in growth arrested GEO cells by autocrine heregulin. Cell lysates from growth arrested GEO cells were analysed for expression of activated AKT, p70S6 kinase and ERK1/2 by Western blot analysis. Cells were also treated with heregulin neutralizing antibody (Hrg-nAb) and AG879 (AG879), LY294002 (LY294002), PD980059 (PD980059) and rapamycin (Rapamycin) at the concentrations of 8 mg/ml, 3, 30, 30 and 0.2 mM respectively. Equivalent amounts of protein were analysed by Western blot with antiphospho Erk (A) or anti-phospho AKT (B) or anti-phospho activated p70S6 kinase (C) antibodies respectively. The corresponding blots were stripped and re-probed with anti-Erk, anti-AKT or anti-p70S6 kinase antibodies respectively for normalization of protein loading 7c). These inhibitors were also utilized to determine whether these constitutively activated pathways were critical to re-entry into the cell cycle by the growth factor independent GEO cells. LY294002 and PD98059 both inhibited DNA synthesis as seen in the mitogenesis assay at the same concentrations which inhibited the PI3K and MAPK pathways, respectively (Figure 6 ). P70S6 kinase is a PI3K intermediate that is required for cell growth and cell proliferation (Grammer et al., 1996) . Treatment with rapamycin, a FRAP/TOR inhibitor that blocks phosphorylation of p70S6 kinase inhibited the activation of p70S6 kinase (Figure 7b) . Moreover, rapamycin (at the same concentration) was shown to inhibit DNA synthesis, thus indicating that p70SK is a critical upstream mediator of re-entry into the cell cycle in addition to the MAPK pathway. The results indicate that both the MAPK and PI3K pathways are critical for re-entry into the cell cycle by growth arrested GEO cells.
PARP cleavage and DNA fragmentation assay
The role of heregulin and ErbB2 activation in promoting cell survival by prevention of apoptosis in growth arrested GEO cells was examined after treatment with heregulin neutralizing antibody or AG879. We determined the cleavage of poly (ADPribose) polymerase (PARP), a well-established substrate of caspase 3 and marker of caspase activation, in GEO cell extracts by Western blots. A band of *85 kD corresponding to a cleavage product of PARP is seen in cells undergoing apoptosis. GEO cells treated with neutralizing antibody to heregulin or with AG879 showed signi®cantly more PARP cleavage product than control cells, thus indicating enhanced apoptosis as a result of blockade of ErbB2 signaling. The small amount of PARP cleavage seen in untreated control cells is due to growth factor and nutrient deprivation. Cells were treated with PD98059, rapamycin and LY294002 to ascertain whether the PI3K or MAPK pathway was involved in the induction of apoptosis. The degree of PARP cleavage seen in samples treated with PD98059 or rapamycin, is the same as with untreated control samples. Thus, inhibition of the MAPK pathway or p70S6 kinase did not induce apoptosis as indicated by lack of an 85 kD cleaved product in GEO cells treated with PD98059 or rapamycin (Figure 8) . However, cells treated with LY294002 had a similar degree of PARP cleavage as those treated with heregulin neutralizing antibody and AG879. These results indicated that the ERK pathway is not as critical as the PI3K pathway in the protection from apoptosis and survival of the growth arrested GEO colon cancer cells. Moreover the lack of eect of rapamycin on apoptosis indicates that AKT, but not p70S6 kinase is the key PI3K intermediate required for cell survival.
Further, since cleavage of cellular chromatin at intra-nucleosomal sites is a characteristic change of DNA integrity in cells undergoing apoptosis, we examined growth arrested GEO cells treated with heregulin neutralizing antibody and AG879 for DNA laddering. Heregulin neutralizing antibody treatment induced apoptosis as early as 12 h following treatment as evidenced by the DNA laddering seen by gel electrophoresis. Cells treated with AG879 induced apoptosis as early as 1 h (Figure 9 ). This con®rms that autocrine heregulin mediated constitutive activation of ErbB2 is required for cell survival in growth arrested GEO colon cancer cells.
Discussion
Growth factor independence is one of the hallmarks of malignant progression. Although previous studies have shown that autocrine heregulin activity involving activation of ErbB2 can contribute to the growth of Figure 8 Induction of apoptosis and PARP cleavage in GEO cells. Growth arrested GEO cells were either untreated (C) or treated with heregulin-neutralizing antibody (Hrg-nAb), AG879 (AG879), PD980059 (PD980059), LY294002 (LY294002) and rapamycin (Rapamycin) at the concentrations of 8 mg/ml, 3 mM, 30 mM, 30 mM and 0.2 mM respectively. Equivalent amounts of protein from these cells were then analysed by Western blot for PARP cleavage, with an anti-PARP antibody Figure 9 Induction of apoptosis and DNA laddering in GEO cells. Growth arrested GEO cells were treated with heregulin neutralizing antibody (Hrg-nAb) or AG879 (AG879) and DNA isolated. Equivalent amounts of DNA from untreated (C) and cells treated for various intervals of time was loaded onto 1% agarose gels containing 0.5 mg/ml-ethidium bromide. Gels were visualized for laddering of DNA and digitally photographed under UV light using an Alpha Imaging system (Alpha Innotech, CA, USA) various types of cancer cells Klapper et al., 2000; Kristt and Yarden, 1996; Slamon et al., 1987) , this study demonstrates for the ®rst time that the resultant heregulin mediated constitutive activation of ErbB2 leads to both the acquisition of independence from exogenous growth factors for reentry into the cell cycle as well as protection against apoptosis. Moreover, the characterization of constitutive downstream signaling from ErbB2 allowed for the discrimination of speci®c roles for various signaling components. Constitutive activation of AKT by ErbB2 was speci®cally essential to cell survival signaling while the MAPK pathway in conjunction with PI3K pathway activation was essential for nutrient (growth factor independent) mediated re-entry into the cell cycle from quiescence and subsequent DNA synthesis. Activation of ErbB2 was shown to be required for induction of both cell survival and growth factor independence by its inhibition with heregulin neutralizing antibodies and the ErbB2 selective inhibitor AG879.
Constitutive activation of ErbB family members is often associated with malignancy while normal cells and poorly tumorigenic cells do not show this under conditions which are not growth permissive. Actively growing cultures of keratinocytes show autocrine TGFa and EGFR activation, clonality of these cells at low density requires an exogenous source of EGFR ligand (Coey et al., 1988; Pittelkow et al., 1993) . Similarly, actively growing colon adenoma cells show autocrine TGFa dependence, but are incapable of clonal growth without exogenous EGF or TGFa (Markowitz et al., 1990) . When exogenous growth factors are removed from previously described early stage, poorly tumorigenic colon cancer cells autocrine TGFa and EGFR expression are down-regulated and EGFR activation is lost during growth arrest (Howell et al., 1998; Jiang et al., 1998) . In contrast, ectopic low-level expression of TGFa prevents its down-regulation during growth arrest of these cells resulting in constitutive EGFR activation and the induction of growth factor independence as well as robust tumorigenicity. Importantly, the level of EGFR activation is no more than that of actively growing exponential wild type cells showing that constitutive activation rather than over expression of EGFR is the key component of progression (Jiang et al., 1998) . The present study provides the demonstration that native malignant cells which have been genetically modi®ed can generate a similar ErbB family constitutive activation leading to a similar highly progressed phenotype such as that previously reported by ectopic TGFa expression in relatively indolent cancer cells derived from early stage malignancies.
Constitutive activation of ErbB2 in cancers is commonly viewed as being the result of dimerization arising from over expression (Hudziak et al., 1987; Karunagaran et al., 1996; Olayioye et al., 2000; Slamon et al., 1989; Worthylake and Wiley, 1997) . Indeed, this is a common mechanism underlying mammary and ovarian carcinoma Morali et al., 1993; Scoccia et al., 1998) .
However, comparison of ErbB2 levels within a panel of human and breast cancer cell lines showed that protein levels of ErbB2 are not over expressed in GEO cells. Consequently, the autocrine heregulin activity of this cell line provides the demonstration of a second mechanism in addition to over expression leading to constitutive activation of ErbB2. Constitutive activation of`normal' levels of ErbB2 then provides the signaling basis for several of the transformed properties of these cells. While autocrine heregulin has not been associated with the growth regulatory pathology of colon cancer, recent immunohistochemical studies of human colon carcinoma have indicated that heregulin, ErbB2 and ErbB3 are often co-expressed in this disease. This suggests that autocrine heregulin/ErbB family loops may be important modulators of aberrant growth in colon cancer as well as other types of cancers (Gullick, 1996; Kapitanovic et al., 1997; Noguchi et al., 1999; Saeki et al., 1995) . It is important to note that there is precedent for low-level constitutive activation of ErbB family members as an underlying cause of human cancers. A truncation mutant of the EGFR leads to its constitutive activation at a low level resulting in unattenuated or constitutive signaling upon which tumorigenic and cell survival properties are dependent (Antonyak et al., 1998; Moscatello et al., 1998) . This mutant which has been found in a number of cancers demonstrates the importance of constitutive activation as an alternative to over-expression in generating aberrant growth properties.
The autocrine hypothesis was formulated as an explanation for the growth advantage of malignant cells over their normal counterparts (Sporn and Todaro, 1980) . Since the formulation of this hypothesis 20 years ago it has become evident that normal cells demonstrate autocrine activities as well. The question arises as to what is the advantage that autocrine activity in cancer cells provides. As discussed above, insofar as we know, normal cells and even immortalized, but non-malignant cells (e.g., colon adenoma cells) do not exhibit independence from exogenous growth factors for cell cycle re-entry nor do they exhibit constitutive cell survival signaling in Go or quiescence. Consequently, the chief growth advantage resulting from autocrine heregulin mediated activation of ErbB2 may be an enhanced ability to reenter the cell cycle from growth arrest in response to nutrient renewal alone and to survive long periods of exposure to conditions which are not growth permissive. Along this line, it has been reported that actively cycling cells constitute a vanishingly low proportion of the malignant cells in colon cancers as well as other solid tumors (Goldie and Coldman, 1979) . Thus, an autocrine loop providing enhanced reentry into the cell cycle and cell survival would be highly advantageous to the development of a tumor. Similarly, these properties would also be highly valuable in the initiation of metastatic deposits, a situation in which the numbers of malignant cells are quite low.
Materials and methods
Antibodies, materials and buffers
Heregulin neutralizing antibody was purchased from Neomarkers (Fremont, CA, USA). Antibodies used for Western analyses were anti-ErbB2, anti-ErbB3, anti-ErbB4, anti-PARP (Santa Cruz Biotechnology), anti-phosphospeci®c p44/42 ERK speci®c (Thr202/Tyr204), anti-phospho-speci®c AKT/PKB (Ser 473), anti-phospho speci®c p70S6 kinase (Thr421/Ser424) (New England Biolabs, Beverly, MA, USA). Selective kinase inhibitors included AG879, an ErbB2 selective kinase inhibitor (Qiu et al., 1998) , PD98059, an inhibitor of MEK, LY2940002, an inhibitor of PI3-kinase and rapamycin, an inhibitor of FRAP/TOR (Calbiochem).
Cell lines
The human colon cancer cell lines HCT116, CBS, FET and GEO were established in-vitro from primary tumors as previously described (Brattain et al., 1984) . They were adapted to grow in serum free medium (SF) that consists of McCoy's 5A medium (Sigma, St Louis, MO, USA) supplemented with pyruvate, vitamins, amino acids, antibiotics, insulin (20 mg/ml Sigma), transferrin (4 mg/ml Sigma) and EGF (10 ng/ml R&D Systems) (Mulder and Brattain, 1989) . Supplemental McCoy's medium (SM) is McCoy's medium supplemented with pyruvate, nutrients and antibiotics, but lacking growth factors. The early and late passage MCF7 cells were obtained from the Michigan Cancer Foundation while SKBR3 breast cancer cells were obtained from ATCC. All breast cancer cell lines were maintained in the same culture medium as colon cancer cells except that they were supplemented with 10% fetal calf serum instead of EGF, insulin and transferrin. Working cultures of GEO cells were maintained in serum free medium at 378C in a humidi®ed atmosphere of 5% CO 2 . Con¯uent cells were growth arrested in SM medium by nutrient and growth factor deprivation for 5 days as described previously (Mulder and Brattain, 1989) . Growth arrested cells (G 0 /G 1 as determined by¯ow cytometry) were then treated for 24 h with heregulin neutralizing antibody at 8 mg/ml or for 6 h with kinase inhibitors prior to collection of cell lysates. As controls, cells were treated for the corresponding times with chicken IgG or DMSO. Growth factor independence was operationally de®ned in this model system by an assay in which cells were growth arrested by nutrient and growth factor deprivation. Upon reaching con¯uency, cells were changed from a growth factor containing medium to a medium without growth factors. Growth arrest occurs because of nutrient and glucose depletion (Jiang et al., 1998) . This procedure led to a greater than 90% of the cells in the Go state of the cell cycle with 5 days as determined by¯ow cytometry (Jiang et al., 1998) . Reentry into the cell cycle and DNA synthesis required only nutrient replenishment, as fresh medium without growth factors was capable of generating a full mitogenic response. In contrast, growth factor dependence was characterized by the requirement for growth factors in the medium to re-enter the cell cycle from growth arrest.
Immunohistochemistry
Thirteen formalin-®xed paran-embedded colonic adenocarcinomas were identi®ed from the archives of Department of Surgical Pathology, University Hospitals of Cleveland, Ohio, USA. In addition, similarly processed xenograft tumor tissue of GEO colon cancer cells grown in athymic nude mice was evaluated for ErbB2 and heregulin expression. Serial 5 mM sections from these blocks were evaluated immunohistochemically for expression of ErbB2 and heregulin using a modi®ed avidin-biotin method according to Hsu (Hsu et al., 1981) . The monoclonal antibody to ErbB2 (Ab15) (Neomarkers 1 ) used was directed at the C-terminal fragment of ErbB2 recognizing the peptide aa1242-1255 (TAEN-PEYLGLDVPV) (van de Vijver et al., 1988) . Monoclonal antibody to heregulin identi®es both a and b isotypes (Ab1, Neomarkers 1 ). Brie¯y, sections were deparanized in xylene and rehydrated. Antigen retrieval was accomplished by microwaving as described (Shi et al., 1991) . Non-speci®c binding of antibodies was blocked by incubation of sections with 10% normal goat serum. Primary antibody diluted in 10% normal goat serum (1 : 100, erbB2 and 1 : 50 heregulin) was used for staining. Sections were then washed thoroughly with PBS (pH 7.4) followed by incubation with goat antimouse biotinylated secondary antibody (1 : 200) (Vector Laboratories, Burlingame). Endogenous peroxidases were then blocked by immersing the sections in 3% hydrogen peroxide and washed with PBS. Detection of bound antibody was performed by incubating in streptavidinbiotinylated horseradish peroxidase (Vector Laboratories) diluted 1 : 200 in 10% normal goat serum. Sections were washed in PBS and exposed to substrate (diaminobenzidine) (Vector Laboratories, Burlingame, CA, USA) according to manufacturer's instructions. Sections were rinsed thoroughly in distilled water and counterstained with 1% methyl-green, air-dried and mounted in Clearium (Surgipath 1 , Richmond, IL, USA). Positive controls for erbB2 included a panel of four invasive ductal carcinomas of the breast. Positive staining of submucosal ganglion cells served as an internal positive control for heregulin. Negative staining was obtained with primary antibody omission or incubation colon cancers and control tissues with pre-immune serum. Photomicrographs were taken using a Nikon E-800 microscope.
Immunoprecipitation and Western blots
Cells were solubilized in Triton extraction buer (50 mM Tris, pH 7.5, 150 mm NaCl, 1% Triton-X 10). Protease inhibitors (BMB) were added with sodium ortho-vanadate 1 mm, sodium¯uoride 1 mm and PMSF 1 mm (Sigma) added as phosphatase inhibitors. Equivalent amounts of protein from clari®ed lysates were incubated with speci®c antibodies overnight at 48C with gentle agitation for immunoprecipitations. Immune complexes were collected with Protein-A agarose (Life Science Technologies) and washed with extraction buer. Total lysates or immuno-precipitated proteins were boiled in sample loading buer and subjected to SDS ± PAGE and blotted onto poly-vinylidene di-¯uoride membranes. The membranes were blocked with 5% nonfat dry milk in TBS (50 mM Tris, pH 7.5 150 mm NaCl) containing 0.05% Tween-20 (TTBS) prior to probing with speci®c antibodies. Membranes were washed before adding the appropriate peroxidase-coupled secondary antibody. Proteins were visualized using the ECL detection system (Amersham). Stripping of membranes was done in SDS buer (62.5 mm Tris pH 6.8, 2% SDS, 100 mm b-mercaptoethanol).
Mitogenesis assay
The mitogenesis assay was performed as described previously (Mulder and Brattain, 1989) . Brie¯y GEO colon cancer cells were plated at a density of 1.2610 5 cells per well, in 6-well plates in serum free McCoy's medium. When the cells reached saturation density (6 days) they were rendered quiescent by growth factor and nutrient deprivation for 5 days in supplemental McCoy's medium. Cells were released from quiescence with either supplemental McCoy's medium (nutrients alone) or serum free medium (nutrients and growth factors). Cells were also pretreated with heregulin neutralizing antibody, AG879, PD98059, LY2940002 or rapamycin in serum free medium and then released from quiescence in the presence of the neutralizing antibody or the inhibitors in serum free McCoy's medium. The cells were pulse-labeled with methyl[ 3 H]thymidine at peak DNA synthesis, 22 h after release from quiescence. DNA synthesis was measured by incorporation of methyl[
3 H]thymidine into trichloroacetic acid precipitable material.
DNA laddering assay
Growth arrested GEO colon cancer cells were treated as mentioned in Materials and methods for the time periods indicated in the ®gure and lysed in DNA lysis buer (10 mM Tris pH 7.5, 20 mm EDTA and 0.5% Triton X-100, 0.5% SDS and 0.5 mg/ml Proteinase K) at 378C for 4 h. The DNA isolated was then treated with RNase and equivalent quantities from samples were loaded onto 1% agarose gels containing 0.5 mg/ml-ethidium bromide. Gels were digitally photographed under UV light using an Alpha Imaging system (Alpha Innotech, CA, USA).
